IGC Pharma (IGC) Equity Income (2011)
IGC Pharma (IGC) reported Equity Income of -$33588.0 for Q4 2011, down 230.02% quarter-over-quarter from $25832.0 in Q3 2011.
IGC Pharma (IGC) Equity Income (2011) Analysis & Trends
IGC Pharma (IGC) has 1 years of Equity Income data on file, last reported at -$33588.0 in Q4 2011.
- Equity Income for Q4 2011 came in at -$33588.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2012 was -$33588.0 (changed N/A YoY), and the FY2017 annual result was $317742.0, changed N/A from the prior year.
- Equity Income fell to -$33588.0 in Q4 2011 per IGC's latest filing, from $25832.0 in the prior quarter.
- Over five years, Equity Income peaked at $36219.0 in Q2 2011 and troughed at -$33588.0 in Q4 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 235,807.00 |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | IGC Pharma | 29.33 Mn | 29.07 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2011 | -33,588.00 |
| Sep 30, 2011 | 25,832.00 |
| Jun 30, 2011 | 36,219.00 |